The results of clinical trials on a large population of the vaccine candidate developed by the Chinese Sinovac laboratory were “extremely positive”. A vaccination campaign could be launched already in December in Brazil, where these tests are being performed.
Some Good news on the Vaccines Front
After the announcement of the suspension of the clinical trials of the vaccine against COVID-19 developed by the British companies AstraZeneca and Oxford, the Chinese laboratory Sinovac presented “extremely positive” results of its vaccine tested in Brazil, said João Doria, governor of São Paulo, in a press conference. The vaccine, called CoronaVac, is currently in Phase 3 clinical trials, the final phase in which thousands of volunteers will be tested. If these good results are confirmed, a vaccination campaign could be launched in Brazil as early as December.
Two doses at 145 USD
The first results of phase 3 clinical trials showed a good immune response without side effects in 98% of patients over 60 years of age. The tests are conducted by the Butantan Public Reference Institute. The latter has the capacity to produce up to 120 million doses by the beginning of 2021. “We will be able to vaccinate Brazilians in São Paulo and throughout the country,” said João Doria. The forecast is that it will be available already in December. However, Jair Bolsonaro the Brazilian president and political opponent of the governor of São Paulo counts on the British vaccine, which was jointly developed by AstraZeneca and Oxford, who are also testing volunteers in Brazil.
Earlier this week, Sinovac Biotech exhibited its vaccine candidate at a trade fair in Beijing. A manager took the opportunity to say that he had “completed the construction of a factory” that can produce 300 million doses per year. Two doses of this vaccine would be needed for effective immunization. These would cost about 145 dollars. The development of this vaccine has become a priority in China, where the pandemic originated. President Xi Jinping has declared that he wants to make it a “global public good”.
AstraZeneca confident in resuming trials
Despite the suspension of its clinical trials, the British pharmaceutical company AstraZeneca declared that its vaccine could be brought to market by the end of the year. “We can still have a vaccine by the end of the year, early next year,” said Pascal Soriot, Group Executive Director, at an online conference on Thursday, September 10. For its part, the World Health Organization (WHO) estimates that no vaccine will be available before mid-2021. “As far as a realistic timetable is concerned, we really do not expect universal vaccination before the middle of next year,” said Margaret Harris, WHO spokeswoman, on Friday 4 September.
Articles You May Like: